Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies

PLoS Medicine

Volumn 7, Issue 5, 2010, Pages

  Blows, Fiona M ^a   Driver, Kristy E ^a   Schmidt, Marjanka K ^b   Broeks, Annegien ^b   van Leeuwen, Flora E ^b   Wesseling, Jelle ^b   Cheang, Maggie C ^c   Gelmon, Karen ^c   Nielsen, Torsten O ^c   Blomqvist, Carl ^d   Heikkila, Päivi ^d   Heikkinen, Tuomas ^d   Nevanlinna, Heli ^d   Akslen, Lars A ^e   Bégin, Louis R ^f   Foulkes, William D ^g   Couch, Fergus J ^h   Wang, Xianshu ^h   Cafourek, Vicky ^h   Olson, Janet E ^h   Baglietto, Laura ⁱ   Giles, Graham G ⁱ   Severi, Gianluca ⁱ   McLean, Catriona A ^j   Southey, Melissa C ^k   Rakha, Emad ^l   Green, Andrew R ^l   Ellis, Ian O ^l   Sherman, Mark E ^m   Lissowska, Jolanta ⁿ   Anderson, William F ^m   Cox, Angela ^o   Cross, Simon S ^o   Reed, Malcolm W R ^o   Provenzano, Elena ^a   Dawson, Sarah Jane ^a   Dunning, Alison M ^a   Humphreys, Manjeet ^a   Easton, Douglas F ^a   García Closas, Montserrat ^m   Caldas, Carlos ^a   Pharoah, Paul D ^a   Huntsman, David ^c   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF BERGEN   (Norway)

^f MCGILL UNIVERSITY   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h MAYO CLINIC   (United States)

ⁱ CANCER EPIDEMIOLOGY CENTRE   (Australia)

^j ALFRED HOSPITAL   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ INSTITUTE OF ONCOLOGY   (Poland)

^o UNIVERSITY OF SHEFFIELD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HORMONE; KERATIN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT RESPONSE; AGED; BREAST TUMOR; META ANALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HORMONES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77953248475     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000279     Document Type: Article

References (34)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
4. Callagy G, Cattaneo E, Daigo Y, Happerfield L, Bobrow LG, et al. (2003) Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12: 27-34.
5. Oh DS, Troester MA, Usary J, Hu Z, He X, et al. (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24: 1656-1664.
6. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750.
7. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374.
8. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
9. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, et al. (2007) Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 50: 434-438.
10. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, et al. (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376.
11. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, et al. (2007) Basal-like phenotype is not associated with patient survival in estrogen- receptor-negative breast cancers. Breast Cancer Res 9: R16.
12. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, et al. (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7: 134
13. Mulligan AM, Pinnaduwage D, Bull SB, O'Malley FP, Andrulis IL (2008) Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. Clin Cancer Res 14: 4168-4174.
14. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, et al. (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295: 1658-1667.
15. Jatoi I, Baum M (1995) Screening for breast cancer, time to think - and stop? Lancet 346: 436-437.
16. Azzato EM, Greenberg D, Shah M, Blows F, Driver KE, et al. (2009) Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? Br J Cancer 100: 1806-1811.
17. Breast Cancer Association Consortium (2006) Commonly studied single- nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98: 1382-1396.
18. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, et al. (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12: 2468-2475.
19. Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, et al. (2007) Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 25: 64-69.
20. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, et al. (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92: 1529-1531.
21. Kilpivaara O, Bartkova J, Eerola H, Syrjakoski K, Vahteristo P, et al. (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113: 575-580.
22. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, et al. (2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40: 844-853.
23. Olson JE, Ingle JN, Ma CX, Pelleymounter LL, Schaid DJ, et al. (2007) A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 102: 237-247.
24. Giles GG, English DR (2002) The Melbourne Collaborative Cohort Study. IARC Sci Publ 156: 69-70.
25. Garcia-Closas M, Egan KM, Newcomb PA, Brinton LA, Titus-Ernstoff L, et al. (2006) Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta- analyses. Hum Genet 119: 376-388.
26. MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, et al. (2004) Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 96: 1866-1869.
27. Rafii S, O'Regan P, Xinarianos G, Azmy I, Stephenson T, et al. (2002) A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum Mol Genet 11: 1433-1438.
28. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, et al. (1997) Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337: 956-962.
29. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, et al. (2005) Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97: 116-126.
30. Stingl J, Caldas C (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7: 791-799.
31. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemo- therapy. Clin Cancer Res 11: 5678-5685.
32. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334.
33. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281.
34. Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, et al. (2010) PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res 12: R1.